Results 271 to 280 of about 166,316 (332)

Cannabigerol reverses mechanical allodynia through α2A‐adrenergic modulation of thalamocortical signaling in chemotherapy‐induced neuropathy

British Journal of Pharmacology, EarlyView.
Abstract Background and Purpose Chemotherapy‐induced peripheral neuropathy (CIPN) is a prevalent and treatment‐resistant side effect of platinum‐based chemotherapy, characterised by mechanical allodynia. Cannabigerol (CBG), a non‐psychoactive cannabinoid, has shown antinociceptive potential, but its site and mechanism of action remain unclear.
Quinn W. Wade, Nathan Morris, Diana E. Sepulveda, Alonso Cortez‐Resendiz, Christopher Brandl, Jennifer E. Lausch, Mariya Starostina, Nicholas M. Graziane   +7 more
wiley   +1 more source

Behavioural Economic Demand for Medicinal and Recreational Cannabis Among People Who Use Over-The-Counter CBD Products, THC Only and CBD + THC. [PDF]

Drug Alcohol Rev
González-Roz A, García-Pérez Á, Cuesta-López I, Alemán-Moussa L, Secades-Villa R.   +4 more
europepmc   +1 more source

Parking Policy Acceptability in Wellington CBD

, 2015
Kate Coles
openalex   +2 more sources

Evaluation of preclinical antipsychotic models used to support first‐in‐human clinical trials

British Journal of Pharmacology, EarlyView.
Abstract Schizophrenia is regarded as a complex and heterogeneous psychiatric disorder, characterised by diverse symptoms and comorbidities, which complicate both clinical management and drug development. Current pharmacological treatment, primarily based on dopamine D2 receptor antagonism or partial agonism, which has not markedly progressed since the
Thi Viet Ha Nguyen, Declan P. McKernan, John P. Kelly   +2 more
wiley   +1 more source

Combined extraction and spray-freeze-drying of Cannabis sativa Flos provides stable lyophilizate particles of cannabinoids. [PDF]

J Cannabis Res
Kožák J, Vázquez-Olvera JI, Berkenfeld K, Rautenberg A, Lamprecht A.   +4 more
europepmc   +1 more source

Epigenetic mechanisms and therapeutic innovations in chronic pain‐associated neuropsychiatric co‐morbidities

British Journal of Pharmacology, EarlyView.
Abstract Chronic pain, marked by nociceptive sensitization and maladaptive neuroplasticity, affects 30% of the global population with escalating socioeconomic burdens. Epidemiological data show a 2‐3‐fold increase in neuropsychiatric co‐morbidities among individuals with chronic pain, where epigenetic dysregulation serves as a key mechanism linking ...
Kai Zhang, Sijia Zhu, Na Xing, Zhen Zhou, Jiayi Chen, Tianen Si, Mingrui Li, Lin Jia, Yousef Rastegar‐Kashkooli, Tom J. Wang, Wei Zhu, Jing Li, Chao Jiang, Junmin Wang, Moxin Wu, Xiaoping Yin, Weidong Zang, Jian Wang, Songxue Su   +18 more
wiley   +1 more source

Cannabidiol-based lipid nanocarriers with analgesic activity. [PDF]

Sci Rep
de Oliveira Sato A, Goulart JPT, Rodrigues TS, Ueira-Vieira C, Bastos LM, Sommerfeld S, Fonseca BB, de Morais Ribeiro LN.   +7 more
europepmc   +1 more source

CBD/THC Interactions

, 2022
openaire   +1 more source

Opioids in breast cancer: Between analgesia and modulation of tumour progression

British Journal of Pharmacology, EarlyView.
Preclinical investigations consistently demonstrate that activation of μ‐opioid receptors and δ‐opioid receptors promote proliferation, migration, angiogenesis, epithelial‐mesenchymal transition, acquisition of cancer stem cell phenotypes, and chemoresistance.
Marianna Ciwun, Anna Tankiewicz‐Kwedlo, Dariusz Pawlak   +2 more
wiley   +1 more source

A temporary spike: Investigating Lennox-Gastaut syndrome incidence in the US following FDA approval of cannabidiol. [PDF]

Epileptic Disord
Marcinski Nascimento KJ, Li Y, Lin BY, Dixon-Salazar T, Perry MS, Xu KY, Nascimento FA.   +6 more
europepmc   +1 more source